EVLO
Evelo Biosciences Inc (EVLO)
$2.1
Key Stats
$2.07
Day's Range
$2.155
$1.42
52-Week Range
$14.2
| Returns | |
| 1 month return | 0.48% |
| 3 month return | 37.8% |
| 1 year return | 84.51% |
| 5 year return | 87.14% |
Company Information
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company's first product candidates are pharmaceutical preparations of single strains of microbes selected for the potential to offer defined pharmacological properties. Evelo's therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.
| Organization | Evelo Biosciences Inc |
| Employees | 2018 |
| CEO | |
| Industry | Health Technology |
Analyst Recommendation
based on 13 analysts ratings
Buy
84%
Buy
15%
Hold
0%
Sell
Based on 13 Wall street analysts offering stock ratings for Evelo Biosciences Inc(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 895.26%Current
$2.11
Target
$21.0
Recommendation Trend
Based on 13 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 11 | 11 | 10 |
| Hold | 2 | 2 | 3 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Company Financials
Highlights
| Market Capitalization | 130.9M |
| Book Value | 0.16 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0 |
| Earnings Share | -2.31 |
| Wall Street Target Price | 19.75 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Sales (ttm) | 0.0 |
| Price/Book (mrq) | 14.92 |
| Enterprise Value | 117.1M |
| Enterprise Value/Revenue | 0.0 |
| Enterprise Value/Ebitda | 0.0 |
Technicals
| Beta | 1.67 |
| 50 Day MA | 3.14 |
| 200 Day MA | 6.88 |
Institutional Holdings
Flagship Ventures Management, Inc.
21.34%
FMR Inc
7.46%
Credit Suisse First Boston (CSFB)
3.31%
Harbourvest Partners, LLC
2.84%
BlackRock Inc
1.95%
Vanguard Group Inc
1.43%
